The broad-spectrum antiviral Remdesivir, a monophosphate nucleoside analogue prodrug (ProTide), was repurposed. In May 2020, it received emergency approval by the FDA, being the first drug approved to fight the new coronavirus (COVID-19) disease which targets the virus directly. The main synthetic strategies toward Remdesivir, and their relevant modifications, are presented and discussed, to provide a panoramic view of the state-of-the-art and the more important advances in this field. Recent progress, proposed improvements, and uses of novel technologies for the synthetic sequence are also detailed.Fil: Vargas Vargas, Didier Farley. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario....
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) ph...
Remdesivir (RDV) is an inhibitor of the viral RNA-dependent RNA polymerases that are active in some ...
Trabajo presentado en el 6th DNA Polymerases meeting, celebrado en Stockholm (Suecia) del 22 al 25 d...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
Infections caused by RNA viruses, such as Ebola and Zika, continue to exist worldwide as significant...
[Figure not available: see fulltext.] The minireview surveys the modification of native nucleosides ...
There has been an increasing interest in remdesivir research within the scientific medical community...
We report an alternative approach to the unnatural nucleobase fragment seen in remdesivir (Veklury)....
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved i...
Cancer and viral infections such as hepatitis B infection and acquired immune deficiency syndrome (A...
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and...
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the o...
The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other ...
Abstract The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can qu...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a se...
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) ph...
Remdesivir (RDV) is an inhibitor of the viral RNA-dependent RNA polymerases that are active in some ...
Trabajo presentado en el 6th DNA Polymerases meeting, celebrado en Stockholm (Suecia) del 22 al 25 d...
COVID-19 patients with severe symptoms still lack antiviral treatment options. Although remdesivir i...
Infections caused by RNA viruses, such as Ebola and Zika, continue to exist worldwide as significant...
[Figure not available: see fulltext.] The minireview surveys the modification of native nucleosides ...
There has been an increasing interest in remdesivir research within the scientific medical community...
We report an alternative approach to the unnatural nucleobase fragment seen in remdesivir (Veklury)....
The development of remdesivir has been a breakthrough for COVID-19 treatment. It has been approved i...
Cancer and viral infections such as hepatitis B infection and acquired immune deficiency syndrome (A...
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and...
Patients and physicians worldwide are facing tremendous health care hazards that are caused by the o...
The coronavirus disease has spread all over the world. Till now no medicine, vaccine, and any other ...
Abstract The ongoing SARS‐CoV‐2 pandemic stresses the need for effective antiviral drugs that can qu...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative representative of a se...
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) ph...
Remdesivir (RDV) is an inhibitor of the viral RNA-dependent RNA polymerases that are active in some ...
Trabajo presentado en el 6th DNA Polymerases meeting, celebrado en Stockholm (Suecia) del 22 al 25 d...